![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 6, 4215-4219, February 11, 2000
From the P311 is a mouse cDNA originally identified
for its high expression in late-stage embryonic brain and adult
cerebellum, hippocampus, and olfactory bulb. The protein product of
P311, however, had not been identified previously, and its function
remains unknown. We report here that P311 expression is regulated at
multiple levels by pathways that control cellular transformation. P311
mRNA expression was decreased sharply in both neural and smooth
muscle cells when the cells were transformed by coexpression of the
oncogenic tyrosine kinase receptor Met and its ligand hepatocyte growth
factor/scatter factor. The P311 mRNA was found to encode an 8-kDa
polypeptide that was subject to rapid degradation by the
lactacystin-sensitive ubiquitin/proteasome system and an unidentified
metalloprotease, resulting in a protein half-life of about 5 min. These
data suggest that P311 expression is dramatically decreased by several
pathways that regulate cellular growth.
Met is a 190-kDa tyrosine kinase receptor that has been implicated
in the etiology of a number of human cancers (for review see Ref. 1).
Met initiates cancerous growth when it is co-expressed constitutively
with its ligand, hepatocyte growth factor/scatter factor
(HGF/SF)1 (2-5), or when it
is activated through germ-line or somatic mutations in its tyrosine
kinase domain (6). The former mechanism plays a role in the generation
of many sarcomas (3), carcinomas (1), melanomas (7), and gliomas (8,
9), whereas the latter plays a role in the generation of familial and
sporadic papillary renal cell carcinoma (6).
Our recent efforts have been aimed at understanding the ability of Met
to initiate primary tumor growth and metastasis at the molecular level,
and toward that end, we have identified several genes whose expression
is regulated by Met action. Many of these genes encode extracellular
matrix proteins or enzymes that degrade these proteins, and this
underscores the profound effect that Met action has on the
extracellular environment of the cell. For instance, Met not only
decreases production of the extracellular matrix protein fibronectin,
but it dramatically decreases cell surface integrin expression, thereby
limiting interaction with matrix
proteins2 (10). In addition,
Met signaling increases production of proteases, such as urokinase,
that degrade the extracellular matrix, (2) whereas Met signaling
reduces the expression of tissue inhibitors of matrix metalloproteases,
which are inhibitors of the matrix metalloproteases that degrade the
extracellular matrix (11). These alterations are thought to increase
invasive growth and deregulate cell cycle pathways.
In the studies described here we used differential display screening to
identify other genes that may be important in Met-mediated tumorigenesis. We found a new Met-HGF/SF-regulated mRNA, P311 (12),
that was down-regulated by Met signaling in several types of
transformed cells. We found that this mRNA encoded a relatively small intracellular protein that was targeted for degradation by
multiple proteolytic pathways including the ubiquitin/proteasome, resulting in an extremely short protein half-life. Therefore, expression of the P311 gene was under tight regulation by several mechanisms that regulate cellular growth.
Cells and Culture--
SK-LMS, HCN-1A, HCN-2, U118, U373, DBTRG,
SK-N-SH, SW-1783, and COS-7 cells were obtained from American Type
Culture Collection (Manassas, VA) and maintained in Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum
(v/v) (Life Technologies, Inc.). SK-LMS cells that stably express
HGF/SF have been described previously (2). Normal human astrocytes
(NHA) (Clonetics, San Diego, CA) were maintained in media provided by
the manufacturer. HCN-1A and HCN-2 were induced to differentiate by
exposure to 25 ng/ml neural growth factor (NGF) (Roche Molecular
Biochemicals), 0.5 mM dibutyrl cAMP (Sigma), and 0.5 mM 3-isobutyl-1-methylxanthine (Sigma) for 3 days.
Northern Blotting--
Total RNA was prepared from cultured
cells using a standard acidic phenol extraction procedure (13). 15-µg
RNA samples were separated on 1.2% agarose/formaldehyde gels and used
for Northern blot analysis as described previously (14). The blots were
probed with a 32P-labeled fragment of the 3'-untranslated
region of the mouse P311 cDNA that was isolated by differential
display screening (see below) or with a 1.2-kilobase pair
PstI fragment of pHcGAP, a human glyceraldehyde-phosphate
dehydrogenase plasmid (15). Probes were also generated from the human
P311 cDNA protein coding region using polymerase chain reactions
and appropriate primers, and their hybridization patterns were
essentially identical to those of the differential display P311
fragment probe.
Differential Display Screening--
Total RNA was isolated from
SK-LMS or SK-LMS/HGF cells and used for differential display screening
with the RNAimage kit 1 (GenHunter Corp., Nashville, TN) according to
protocols supplied by the manufacturer. One cDNA fragment isolated
using primers H-T11A and H-AP2 corresponded to a
280-nucleotide fragment of the 3' end of the human P311 cDNA
(GenBankTM U30521).
Expression Vectors--
Using appropriate primers, SK-LMS
cDNA, and polymerase chain reactions, the human P311 cDNA
coding region was cloned into the pRcCMV (Invitrogen, Carlsbad, CA)
expression vector. The FLAG epitope tag, DYKDDDDK, was cloned onto the
5' or 3' edge of this cDNA fragment by inserting sequences coding
those amino acids into the polymerase chain reaction primers. The
plasmids were transfected into cells using the SuperFect kit (Qiagen,
Valencia, CA).
Immunoprecipitation--
The immunoprecipitation protocol has
previously been described in detail (16). Cells were plated onto 60-mm
plates, grown to confluence, and labeled in Cys/Met-free Dulbecco's
modified Eagle's medium (Life Technologies, Inc.) supplemented with
10% fetal bovine serum (v/v) and 0.5 mCi
[35S]-EXPRE35S35S protein
labeling mix (NEN Life Science Products). Cell lysates were prepared
and used for immunoprecipitation with the monoclonal M2 anti-FLAG
antibody (Eastman Kodak Co.), or rabbit polyclonal anti-P311 antisera
raised against the peptide CGSSELRSPRISYLHFF, corresponding to the
human P311 C-terminal sequence. Precipitated proteins were resolved by
10% tricine gel electrophoresis, and the resulting gels were used for
autoradiography. In some experiments the cells were exposed to 10 µM lactacystin (Boston Biochem, Boston, MA), 2 µg/ml
aprotinin, 0.68 µg/ml pepstatin A, 24 µg/ml leupeptin, 0.2 mg/ml
(1.26 mM) o-phenanthroline, or 1.26 mM 4,7-phenanthroline prior to and during the labeling period.
Immunofluorescence Assays--
NHA were grown on
poly-L-lysine-coated, four-well glass chamber slides
(12-550-51 SuperCell culture slides; Fisher) until they reached about
50% confluency. The cells were fixed in 4% paraformaldehyde (w/v) for
15 min, permeabilized with 0.2% Triton X-100 in phosphate-buffered
saline for 10 min, and blocked with 10% goat serum (v/v), 0.1% Tween
20 (v/v) in phosphate-buffered saline for 1 h. The cells were then
incubated for 60 min with 1:50 dilutions of a polyclonal
anti-C-terminal P311 antibody (see "Immunoprecipitation") or a
polyclonal P311 antibody that recognized the internal sequence
KGRLPVPKEVNRKK. In some experiments the cells were costained with 1:400
dilutions of a mouse monoclonal anti-vinculin antibody (Sigma).
Finally, the cells were incubated for 30 min with 1:100 dilutions of a
fluorescein isothiocyanate-conjugated anti-rabbit antibody (Roche
Molecular Biochemicals) and/or a rhodamine-conjugated anti-mouse
antibody (Roche Molecular Biochemicals). The cells were observed and
images were analyzed using a Zeiss LSM310 confocal laser scanning
microscope; it was configured with a 25-milliwatt argon internal HeNe
laser. Nomarski images were made using the 543 laser and appropriate
polarizer lenses.
Nude Mouse Tumor Studies--
Nude mouse protocols have
previously been described in detail (2). 106 cells were
injected subcutaneously into athymic nude mice that were monitored
daily for tumor growth.
Identification of P311 as a Met-HGF/SF-regulated Gene--
To
identify genes regulated by Met-HGF/SF signaling we used differential
display screening to compare cDNAs from a cell line with low
Met-HGF/SF signaling to the same cells engineered to have high
signaling. The cells we chose were SK-LMS cells, which were originally
derived from a human leiomeiosarcoma; we have shown previously that
they express high levels of Met but virtually no HGF/SF and in nude
mouse tumor assays, that they are non-metastatic and only weakly
tumorigenic (2). However, when they stably express exogenous HGF/SF,
generating an autocrine loop, the cells become metastatic and much more
tumorigenic, decreasing the tumor latency period from 10 to 5 weeks
(2). In the present study we identified a differentially displayed
cDNA fragment that was present at moderately high levels in
parental SK-LMS cells and at substantially lower levels in a pool of
SK-LMS/HGF cells (data not shown); we subsequently verified this result
using the fragment as a probe for a Northern blot (Fig.
1). Cloning and sequencing revealed that
the cDNA fragment corresponded to 280 nucleotides from the
3'-untranslated region of P311, a cDNA whose mouse homolog is
highly expressed in late-stage embryonic brain and adult cerebellum, hippocampus, and olfactory bulb but for which no function has been
described (12). The effect of HGF/SF in decreasing P311 expression in
SK-LMS cells required constitutive exposure to the cytokine, in that
exposure of parental SK-LMS cells to a single dose of HGF/SF did not
appreciably lower P311 mRNA levels (data not shown). Because SK-LMS
cells are transformed smooth muscle cells we also examined P311
expression in normal human intestinal smooth muscle cells, in which we
found extremely high P311 mRNA levels (Fig. 1), suggesting a
progressive decrease in P311 expression in increasingly more
transformed smooth muscle cells.
We also measured P311 levels in tumors derived from SK-LMS and
SK-LMS/HGF cells (Fig. 2). The moderately
high P311 expression in the parental cells was decreased to very low
levels in two tumor explants of these cells (Fig. 2), an effect that
may be partially explained by increased Met-HGF/SF signaling in the
tumor cells that we have demonstrated previously (2). In tumor explants from SK-LMS/HGF cells, P311 levels remained very low (Fig. 2). Therefore, low P311 expression correlated with increased Met-HGF/SF signaling and tumorigenic growth of SK-LMS cells.
P311 Expression in Neural Cells--
Next we examined other cells
for the effect of Met-HGF/SF on P311 expression. Because P311 is
expressed at its highest levels in brain (12) we measured mRNA
levels in NHA and in several glioma cell lines that express high levels
of both Met and HGF/SF; autocrine Met-HGF/SF signaling in these gliomas
is thought to contribute to their transformation (8). We found
extremely high P311 expression in NHA cells (Fig.
3) at levels comparable with those in
normal smooth muscle cells (Fig. 1 and data not shown), whereas each of
the glioma cell lines had much lower expression (Fig. 3). In the case
of U118 glioma cells the low P311 expression was due, at least in part,
to Met-HGF/SF action, because addition of a neutralizing HGF/SF
antibody to the cell's culture medium increased P311 mRNA levels
(data not shown).
We also examined whether terminal differentiation of normal neural
cells resulted in loss of P311 expression just as transformation of
neural cells did. For these experiments we used HCN-1A and HCN-2 cells;
these are human cerebral cortical pre-neuronal cell lines that can be
induced to differentiate into neuron-like cells by exposure to NGF
(17). Both HCN-1A and HCN-2 cells expressed very high levels of P311
mRNA similar to those in NHA, but these levels were decreased when
the cells were induced to differentiate by NGF treatment (Fig.
4). Therefore, differentiation, as well as transformation, of neural cells resulted in loss of P311
expression.
Instability of the P311 Protein--
Prior to the studies
described here the P311 protein product had not been identified, and in
fact it was unclear whether the mRNA was translated in
vivo (12). The human P311 cDNA contains three open reading
frames, but only the first reading frame, which encodes a 68-amino acid
polypeptide, is conserved among the human, mouse, and chicken P311
cDNAs (12). Therefore, to begin our studies of the protein we
generated P311 expression vectors in which this putative protein coding
sequence was linked to a FLAG epitope tag at either its N or C
terminus. After transient expression of these vectors in COS-7 cells we
were able to detect FLAG-P311 and P311-FLAG protein by
immunoprecipitation with an anti-FLAG antibody (Fig.
5). However, detection of the protein was
only possible if the cells were radiolabeled for very short periods of
time (5-10 min); longer labeling times resulting in backgrounds too
high to distinguish the 8-kDa band. This suggested that the protein was
unstable, and we confirmed this in a pulse-chase experiment in which we
found FLAG-P311 to decay with a half-life of about 5 min (Fig.
6).
Extremely rapid decay of P311 protein suggested that it may be targeted
by a specific intracellular proteolysis system. One such system is the
ubiquitin/proteasome system, which degrades proteins with PEST domains
by covalently linking ubiquitin to lysine residues of the protein,
thereby allowing recognition and degradation of the protein by the
proteasome (for review see Ref. 18). Because P311 contains PEST domains
as well as lysine residues we examined it for proteasome-mediated
degradation by conducting a pulse-chase experiment in the presence of
the proteasome inhibitor lactacystin (19) (Fig.
7). In the presence of this inhibitor essentially no degradation of FLAG-P311 took place during the 30-min
period of the experiment (Fig. 7) demonstrating that FLAG-P311 was
targeted by the proteasome system.
Next we examined expression of wild-type P311 that lacked a FLAG
epitope tag. Two polyclonal antisera were raised against P311, one that
recognized an internal sequence and another a C-terminal sequence. Both
of them were able to immunoprecipitate the 8-kDa P311 band from NHA
lysates, and this band was seen only in cell lysates and not in
conditioned media (data not shown). We assessed the stability of
wild-type P311 in a pulse-chase experiment following transient
expression of wild-type P311 in COS-7 cells, and, as expected, it
decayed very rapidly with a half-life of about 5 min (Fig.
8 and data not shown). Surprisingly,
however, lactacystin did not block decay of the protein (Fig. 8),
demonstrating that some other protease that had not been active against
FLAG-P311 degraded wild-type P311. To determine the nature of this
protease we performed pulse-chase experiments in which cells were
treated with lactacystin in combination with a series of protease
inhibitors including o-phenanthroline, pepstatin, leupeptin,
and aprotinin. Only the combination of lactacystin and the
metalloprotease inhibitor, o-phenanthroline, was able to
block degradation of P311 (Fig. 8 and data not shown). In contrast, a
combination of lactacystin and 4,7-phenanthroline, a non-chelating
analog of o-phenanthroline, did not block degradation,
implying that the ability of o-phenanthroline to inhibit
P311 degradation required its chelating capacity. Taken together, these
data suggested that P311 was subject to rapid degradation by both the
ubiquitin/proteasome system and an unknown metalloprotease. The reason
that the addition of the FLAG epitope to P311 blocked degradation by
the metalloprotease was not determined. In other experiments we found
that endogenous P311 in normal human smooth muscle cells also had a
very short half-life and that its degradation also could be blocked by
the lactacystin/o-phenanthroline combination (data not
shown). In all of the experiments in which cells were exposed to
lactacystin and o-phenanthroline we detected a slightly
smaller band (Fig. 8), similar in size to a band precipitated from P311
in vitro translations (Fig. 5). This band may result from
translation initiation from an internal ATG at codon 21 (12).
P311 Detection in the Nucleus and Cytosol--
We examined the
subcellular localization of endogenous P311 by immunocytochemistry of
normal human astrocytes. Two different antisera that recognized
distinct P311 regions showed similar patterns, with staining of
nucleoli in all cells and staining of focal adhesions in some cells
(Fig. 9C and data not shown). Focal adhesion staining occurred only along the leading edge of cells
with an obvious motile morphology. Simultaneous staining with
monoclonal antibodies recognizing the focal adhesion protein, vinculin
(20), showed colocalization of P311 and vinculin in the focal adhesions
(Fig. 9C). In related biochemical experiments we
fractionated pulse-labeled cells into nuclear and cytosolic fractions
and used each fraction for P311 immunoprecipitation. Again, P311 was
present in both fractions with slightly higher levels in the cytosol
(data not shown).
The Effect of P311 Overexpression on Tumorigenicity--
To
determine whether overexpression of P311 had a direct effect on the
tumorigenicity of U118 cells we stably transfected them with the
P311-FLAG expression vector. A pool of cells that expressed high levels
of P311-FLAG mRNA (data not shown) was injected subcutaneously into
nude mice along with the parental U118 cells. Within about 4 weeks both
groups of cells formed palpable tumors that slowly increased in size at
about equal rates (not shown). At 10 weeks we isolated the tumors and
found that exogenous P311-FLAG expression remained high, at levels
comparable with those of the input pool of cells (not shown).
Therefore, P311 overexpression did not interfere with the tumorigenic
growth of U118 cells.
We have shown that P311 expression is tightly regulated at several
levels by mechanisms that control cellular growth and transformation. At the mRNA level we found that P311 expression was reduced
substantially in both smooth muscle and neural cells transformed by
coexpression of Met and its ligand, HGF/SF. Signaling through Met
initiates transformation of a wide variety of mesenchymal and
epithelial cells (1), but the down-stream molecular pathways that are important in their transformation have not been completely delineated. Regulation of P311 expression is thus a novel pathway that could be of
importance for Met-induced tumor growth. Overexpression of P311 in U118
glioma cells, in which Met-HGF/SF signaling is active, did not
interfere with tumorigenic growth, implying that P311 does not have a
dominant tumor suppressor function in that context. However, the strong
correlation between loss of P311 expression and tumorigenesis suggests
that low P311 could be a contributing factor to tumorigenesis. In
addition, P311 may be a useful marker for distinguishing between normal
and transformed smooth muscle or neural tissue.
We also found that P311 expression was controlled at the level of
protein stability. In both smooth muscle and neural cells the protein
had a half-life of 5 min or less, with the rapid degradation being
directed by two pathways: the ubiquitin/proteasome system and a
metalloprotease whose identity we have not determined. Ubiquitin is a
76-residue protein that is covalently linked to lysines of proteins
with PEST sequences, thereby tagging the proteins for degradation by
the proteasome (18). This pathway is thought to regulate major
biological processes including the cell cycle, cellular
differentiation, and neural function (18). For instance, the p53 tumor
suppressor protein is subject to ubiquitin-proteasome degradation as a
result of its association with mdm2, and this profoundly influences p53
function and consequently, cellular growth (21, 22). A second protein
subject to rapid turnover by the proteasome is p35, a neuronal-specific
activator of cyclin-dependent kinase 5, that drives
neuronal migration and development of the mammalian cortex (23). Thus,
P311 represents another protein that has links to neural function and
cellular transformation/differentiation and that is turned over rapidly
by the proteasome.
Although our studies propose the involvement of P311 in cellular growth
and differentiation, the function of the protein remains unknown. The
primary amino acid sequence of P311 is apparently novel among proteins
in the current data bases and thus suggests no function. In the
immunostaining experiments the protein was present in both the nucleus
and the cytosol. The nuclear localization was found in all cells, but
the cytosolic localization occurred only in those cells with a motile
morphology, with the protein concentrated along the periphery of the
cells in focal adhesions. This suggests that the protein could be
involved in the processes of gene expression or cellular motility or
could possibly form a link between the two. The apparent increase in
P311 concentrations in motile cells may represent another level at
which its expression is regulated. It may also explain why the overall
concentration of P311 in a population of cells seems to be quite low
and precluded attempts to detect the protein by Western blotting. Based
on our studies, future work should address the potential roles of P311 in cellular differentiation, transformation, and motility.
We thank Michelle Reed and Ave Cline for
assistance in preparing the manuscript and Richard Frederickson for
assistance in preparing the figures.
*
This research was sponsored in part by the NCI, Department
of Health and Human Services under Advanced Bioscience Laboratories Contract NO1-CO-46000.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Current Address: Dept. of Medicine, Duke University, and Veterans
Affairs Medical Center, Durham, NC 27705.
¶
Current Address: Van Andel Research Inst., Grand Rapids, MI 49503.
**
To whom correspondence should be addressed: Van Andel
Research Inst., 201 Monroe Ave., N.W., Suite 400, Grand Rapids, MI
49503; Tel.: 616-235-8242; Fax: 616-235-8245; E-mail:
george.vandewoude@vai.org.
2
G. A. Taylor and G. F. Vande Woude,
unpublished data.
The abbreviations used are:
HGF, hepatocyte
growth factor;
SF, scatter factor;
HCN, human cortical neuronal cells;
NHA, normal human astrocytes;
NGF, neural growth factor;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Regulation of P311 Expression by Met-Hepatocyte Growth
Factor/Scatter Factor and the Ubiquitin/Proteasome System*
§,
¶,
¶, and
**
Advanced Bioscience Laboratories Basic
Research Program and the
National Cancer Institute,
NCI-Frederick Cancer Research and Development Center, Frederick,
Maryland 21702
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (29K):
[in a new window]
Fig. 1.
P311 expression in normal and transformed
smooth muscle. Total RNA was isolated from human intestinal smooth
muscle cells (HISM), SK-LMS, and SK-LMS/HGF cells and used
for sequential Northern blotting with P311 and GAPDH probes. The
positions of the major ribosomal RNA species as determined by the
stained gel are indicated. Other details are described in the
text.

View larger version (47K):
[in a new window]
Fig. 2.
P311 expression in tumors derived from SK-LMS
and SK-LMS/HGF cells. SK-LMS and SK-LMS/HGF cells were injected
subcutaneously into nude mice; cells explanted (EP) from the
resulting tumors were used for sequential Northern blotting with P311
and GAPDH probes. Positions of the major ribosomal mRNA species as
determined from the stained gel are indicated.

View larger version (44K):
[in a new window]
Fig. 3.
Expression of P311 in neural-derived
tumors. Total RNA was isolated from NHA or the indicated neural
tumor cell lines and used for sequential Northern blotting with a P311
and GAPDH probes. The positions of the major ribosomal mRNA species
as determined from the stained gel are indicated.

View larger version (53K):
[in a new window]
Fig. 4.
Effect of neural differentiation on P311
expression. NHA, HCN-1A, and HCN-2 cells were incubated under
control conditions or induced to differentiate by exposure to NGF,
cAMP, and 3-isobutyl-1-methylxanthine for 3 days. Total RNA was
isolated and used for sequential Northern blotting with P311 probe and
GAPDH probes. The positions of the major ribosomal mRNA species as
determined from the stained gel are indicated.

View larger version (33K):
[in a new window]
Fig. 5.
Detection of P311-FLAG and FLAG-P311
proteins. COS-7 cells were transiently transfected with pRcCMV
vector (Control) or vectors expressing P311-FLAG and
FLAG-P311 proteins. These cells were pulse-labeled for 8 min with
[35S]Met/Cys, and lysates from the cells were used for
immunoprecipitation with anti-FLAG antibodies. In vitro
translated P311-FLAG was also precipitated with anti-FLAG antibodies
(lane 1). The precipitated proteins were resolved by 10%
tricine gel electrophoresis. The positions of selected molecular mass
markers are shown on the left. Ab,
antibody.

View larger version (41K):
[in a new window]
Fig. 6.
Rapid decay of FLAG-P311 protein. COS-7
cells were transiently transfected with a vector expressing FLAG-P311
protein. 24 h later the cells were pulse-labeled for 8 min with
[35S]Met/Cys and then exposed to unlabeled amino acids
for the indicated times. Lysates from the cells were used for
immunoprecipitation with anti-FLAG antibodies. The precipitated
proteins were resolved by 10% tricine gel electrophoresis. The
positions of selected molecular mass markers are shown on the
left.

View larger version (39K):
[in a new window]
Fig. 7.
Effect of lactacystin on FLAG-P311 protein
half-life. COS-7 cells were transiently transfected with a vector
expressing FLAG-P311 protein. These cells were preincubated for 2 h with lactacystin or maintained under control conditions. The cells
were pulse-labeled with amino acids for 8 min and then exposed to
unlabeled amino acids for the indicated times, under the continuing
presence or absence of lactacystin. Lysates from the cells were used
for immunoprecipitation with anti-FLAG antibodies. The precipitated
proteins were resolved by 10% tricine gel electrophoresis. The
positions of selected molecular mass markers are shown on the
left.

View larger version (46K):
[in a new window]
Fig. 8.
Effect of lactacystin and
o-phenanthroline on P311 protein half-life. COS-7
cells were transiently transfected with a vector expressing the
wild-type P311 protein. These cells were preincubated for 2 h with
lactacystin, with lactacystin and o-phenanthroline combined,
or maintained under control conditions. The cells were pulse-labeled
with radiolabeled amino acids for 8 min and then chased with unlabeled
amino acids for the indicated times, under the continuing presence or
absence of the protease inhibitors. Lysates from the cells were used
for immunoprecipitation with anti-FLAG antibodies. The precipitated
proteins were resolved by 10% tricine gel electrophoresis. The
positions of selected molecular mass markers are shown on the
left.

View larger version (107K):
[in a new window]
Fig. 9.
P311 immunofluorescence in normal human
astrocytes. Cells grown on glass slides were stained with
pre-immune rabbit primary antibodies (A) or both rabbit
anti-P311 (C-terminal) and mouse anti-vinculin primary antibodies
(C), followed by both fluorescein-conjugated anti-rabbit and
rhodamine-conjugated anti-mouse secondary antibodies. The staining was
analyzed and enhanced with a Zeiss LSM310 confocal laser scanning
microscope in the confocal mode. P311 staining is shown in
green, vinculin staining in red, and
P311/vinculin co-staining in yellow or orange.
Nomarski images of the cells (B and D) correspond
to the antibody-stained cells (A and
C).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Jeffers, M.,
Rong, S.,
and Vande Woude, G. F.
(1996)
J. Mol. Med.
74,
505-513[CrossRef][Medline]
[Order article via Infotrieve]
2.
Jeffers, M.,
Rong, S.,
and Vande Woude, G. F.
(1996)
Mol. Cell. Biol.
16,
1115-1125[Abstract]
3.
Rong, S.,
Jeffers, M.,
Resau, J. H.,
Tsarfaty, I.,
Oskarsson, M.,
and Vande Woude, G. F.
(1993a)
Cancer Res.
53,
5355-5360 4.
Rong, S.,
Oskarsson, M.,
Faletto, D.,
Tsarfaty, I.,
Resau, J. H.,
Nakamura, T.,
Rosen, E.,
Hopkins, R. F. R.,
and Vande Woude, G. F.
(1993b)
Cell Growth Differ.
4,
563-569[Abstract]
5.
Rong, S.,
Segal, S.,
Anver, M.,
Resau, J. H.,
and Vande Woude, G. F.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
4731-4735 6.
Schmidt, L.,
Duh, R.-M.,
Chen, F.,
Kishida, T.,
Glenn, G.,
Choyke, P.,
Scherer, S. W.,
Zhuang, Z.,
Lubensky, I.,
Dean, M.,
Allilmets, R.,
Chidambaram, A.,
Bergerheim, U. R.,
Feltis, J. T.,
Casadevall, C.,
Zamarron, A.,
Bernues, M.,
Richard, S.,
Lips, C. J. M.,
Walter, M. M.,
Tsui, L.-C.,
Geil, L.,
Orcutt, M. L.,
Stackhouse, T.,
Lipan, J.,
Slife, L.,
Brauch, H.,
Decker, J.,
Niehans, G.,
Hughson, M. D.,
Moch, H.,
Storkel, S.,
Lerman, M. I.,
Linehan, W. M.,
and Zbar, B.
(1997)
Nat. Genet.
16,
68-73[CrossRef][Medline]
[Order article via Infotrieve]
7.
Saitoh, K.,
Takahashi, H.,
Sawada, N.,
and Parsons, P. G.
(1994)
J. Pathol.
174,
191-199[CrossRef][Medline]
[Order article via Infotrieve]
8.
Koochekpour, S.,
Jeffers, M.,
Rulong, S.,
Klineberg, E.,
Taylor, G.,
Hudson, E. A.,
Resua, J. H.,
and Vande Woude, G. H.
(1997)
Cancer Res.
57,
5391-5398 9.
Laterra, J.,
Nam, M.,
Rosen, E.,
Rao, J. S.,
Lamszus, K.,
Goldberg, I. D.,
and Johnston, P.
(1997)
Lab. Invest.
76,
565-577[Medline]
[Order article via Infotrieve]
10.
Taylor, G. A.,
Jeffers, M.,
Webb, C. P.,
Koo, H.-M.,
Anvre, M.,
Sekiguchi, K.,
and Vande Woude, G. F.
(1998)
Oncogene
17,
1179-1183[CrossRef][Medline]
[Order article via Infotrieve]
11.
Koochekpour, S.,
Jeffers, M.,
Wang, P. H.,
Gong, C.,
Taylor, G. A.,
Roessler, L. M.,
Stearman, R.,
Vasselli, J. R.,
Stetler-Stevenson, W. G.,
Kaelin, W. G.,
Linehan, W. M.,
Klausner, R. D.,
Gnarra, J. R.,
and Vande Woude, G. F.
(1999)
Mol. Cell. Biol.
19,
5902-5912 12.
Studler, J.-M.,
Glowunski, J.,
and Levi-Strauss, M.
(1993)
Eur. J. Neurosci.
5,
614-623[CrossRef][Medline]
[Order article via Infotrieve]
13.
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
14.
Stumpo, D. J.,
Graff, J. M.,
Albert, K. A.,
Greengard, P.,
and Blackshear, P. J.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
4012-4016 15.
Tso, J. Y.,
Sun, X. H.,
Kao, T.-h.,
Reece, K. S.,
and Wu, R.
(1985)
Nucleic Acids Res.
13,
2485-2502 16.
Taylor, G. A.,
Jeffers, M.,
Largaespada, D. A.,
Jenkins, N. A.,
Copeland, N. G.,
and Vande Woude, G. F.
(1996)
J. Biol. Chem.
271,
20399-20405 17.
Ronnett, G. V.,
Hester, L. D.,
Nye, J. S.,
and Snyder, S. H.
(1994)
Neuroscience
63,
1081-1099[CrossRef][Medline]
[Order article via Infotrieve]
18.
Varshavsky, A.
(1997)
Trends Biochem. Sci.
22,
383-387[CrossRef][Medline]
[Order article via Infotrieve]
19.
Dick, L. R.,
Cruikshank, A. A.,
Destree, A. T.,
Grenier, L.,
McCormack, T. A.,
Melandri, F. D.,
Nunes, S. L.,
Palombella, V. J.,
Parent, L. A.,
Plamondon, L.,
and Stein, R. L.
(1997)
J. Biol. Chem.
272,
182-188 20.
Geiger, B.,
Tokuyasu, K. T.,
Dutton, A. H.,
and Singer, S. J.
(1980)
Proc. Natl. Sci. U. S. A.
77,
4127-4131 21.
Kubbutat, M. H.,
Jones, S. N.,
and Vousden, K. H.
(1997)
Nature
387,
299-303[CrossRef][Medline]
[Order article via Infotrieve]
22.
Crook, T.,
Ludwig, R. L.,
Marston, N. J.,
Willkomm, D.,
and Vousden, K. H.
(1996)
Virology
217,
285-292[CrossRef][Medline]
[Order article via Infotrieve]
23.
Patrick, G. N.,
Zhou, P.,
Kwon, Y. T.,
Howley, P. M.,
and Tsai, L. H.
(1998)
J. Biol. Chem.
273,
24057-24064
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhao, J. K. Leung, H. Yamamoto, S. Goswami, F. Kheradmand, and T. H. Vu Identification of P311 as a Potential Gene Regulating Alveolar Generation Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 48 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. da Costa, C. McGillivray, Q. Bai, J. D. Wood, G. Evans, and K.-C. Chang Restriction of Dietary Energy and Protein Induces Molecular Changes in Young Porcine Skeletal Muscles J. Nutr., September 1, 2004; 134(9): 2191 - 2199. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. JAGOE, S. H. LECKER, M. GOMES, and A. L. GOLDBERG Patterns of gene expression in atrophying skeletal muscles: response to food deprivation FASEB J, November 1, 2002; 16(13): 1697 - 1712. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Demayo, P. Minoo, C. G. Plopper, L. Schuger, J. Shannon, and J. S. Torday Mesenchymal-epithelial interactions in lung development and repair: are modeling and remodeling the same process? Am J Physiol Lung Cell Mol Physiol, September 1, 2002; 283(3): L510 - L517. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Mariani, J. J. Reed, and S. D. Shapiro Expression Profiling of the Developing Mouse Lung . Insights into the Establishment of the Extracellular Matrix Am. J. Respir. Cell Mol. Biol., May 1, 2002; 26(5): 541 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Baran, P. A. Kelly, and N. Binart Characterization of a Prolactin-Regulated Gene in Reproductive Tissues Usingthe Prolactin Receptor Knockout Mouse Model Biol Reprod, April 1, 2002; 66(4): 1210 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mariani, W. S. McDonough, D. B. Hoelzinger, C. Beaudry, E. Kaczmarek, S. W. Coons, A. Giese, M. Moghaddam, R. W. Seiler, and M. E. Berens Identification and Validation of P311 as a Glioblastoma Invasion Gene Using Laser Capture Microdissection Cancer Res., May 1, 2001; 61(10): 4190 - 4196. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |